Candriam Luxembourg S.C.A. lifted its stake in Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA) by 15.0% in the third quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 422,000 shares of the biotechnology company’s stock after acquiring an additional 55,000 shares during the quarter. Candriam Luxembourg S.C.A. owned 0.55% of Momenta Pharmaceuticals worth $7,807,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds also recently made changes to their positions in the company. New York State Common Retirement Fund grew its stake in shares of Momenta Pharmaceuticals by 9.4% in the second quarter. New York State Common Retirement Fund now owns 286,453 shares of the biotechnology company’s stock worth $4,841,000 after acquiring an additional 24,715 shares during the period. BlackRock Inc. grew its position in Momenta Pharmaceuticals by 7.1% during the second quarter. BlackRock Inc. now owns 9,400,485 shares of the biotechnology company’s stock valued at $158,868,000 after buying an additional 626,415 shares during the period. Great West Life Assurance Co. Can grew its position in Momenta Pharmaceuticals by 8.4% during the second quarter. Great West Life Assurance Co. Can now owns 96,471 shares of the biotechnology company’s stock valued at $1,625,000 after buying an additional 7,450 shares during the period. Rhumbline Advisers grew its position in Momenta Pharmaceuticals by 8.6% during the second quarter. Rhumbline Advisers now owns 140,215 shares of the biotechnology company’s stock valued at $2,370,000 after buying an additional 11,128 shares during the period. Finally, Schwab Charles Investment Management Inc. grew its position in Momenta Pharmaceuticals by 22.1% during the second quarter. Schwab Charles Investment Management Inc. now owns 358,055 shares of the biotechnology company’s stock valued at $6,052,000 after buying an additional 64,817 shares during the period. Hedge funds and other institutional investors own 93.92% of the company’s stock.

Momenta Pharmaceuticals, Inc. (NASDAQ MNTA) traded down $0.15 during mid-day trading on Friday, hitting $13.10. 452,200 shares of the stock traded hands, compared to its average volume of 770,821. Momenta Pharmaceuticals, Inc. has a 1 year low of $11.85 and a 1 year high of $19.90.

Momenta Pharmaceuticals (NASDAQ:MNTA) last announced its quarterly earnings results on Wednesday, November 1st. The biotechnology company reported ($0.44) earnings per share for the quarter, topping the consensus estimate of ($0.47) by $0.03. Momenta Pharmaceuticals had a negative net margin of 55.61% and a negative return on equity of 16.20%. The company had revenue of $24.09 million for the quarter, compared to analysts’ expectations of $29.58 million. During the same quarter in the previous year, the business posted ($0.26) earnings per share. Momenta Pharmaceuticals’s quarterly revenue was down 17.3% on a year-over-year basis. research analysts expect that Momenta Pharmaceuticals, Inc. will post -1.16 EPS for the current fiscal year.

In other Momenta Pharmaceuticals news, President Craig A. Wheeler sold 4,116 shares of the business’s stock in a transaction on Monday, August 21st. The shares were sold at an average price of $15.07, for a total transaction of $62,028.12. Following the transaction, the president now owns 269,231 shares in the company, valued at $4,057,311.17. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, President Craig A. Wheeler sold 35,667 shares of the business’s stock in a transaction on Thursday, September 28th. The shares were sold at an average price of $19.03, for a total transaction of $678,743.01. Following the transaction, the president now owns 286,121 shares in the company, valued at approximately $5,444,882.63. The disclosure for this sale can be found here. Insiders sold 61,773 shares of company stock worth $1,111,680 in the last 90 days. 4.40% of the stock is currently owned by company insiders.

TRADEMARK VIOLATION NOTICE: This news story was originally published by The Cerbat Gem and is the property of of The Cerbat Gem. If you are reading this news story on another domain, it was stolen and republished in violation of US & international trademark and copyright laws. The correct version of this news story can be accessed at https://www.thecerbatgem.com/2017/11/12/momenta-pharmaceuticals-inc-mnta-shares-bought-by-candriam-luxembourg-s-c-a.html.

Several analysts recently issued reports on the stock. Cowen and Company set a $15.00 target price on shares of Momenta Pharmaceuticals and gave the company a “hold” rating in a research report on Wednesday, November 1st. Zacks Investment Research lowered shares of Momenta Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Wednesday, October 11th. Robert W. Baird downgraded shares of Momenta Pharmaceuticals from a “buy” rating to a “hold” rating and lowered their price target for the company from $22.00 to $15.00 in a report on Friday, October 6th. ValuEngine downgraded shares of Momenta Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Friday, October 6th. Finally, J P Morgan Chase & Co reaffirmed a “hold” rating and set a $14.00 price target on shares of Momenta Pharmaceuticals in a report on Thursday, October 5th. Three research analysts have rated the stock with a sell rating and nine have given a hold rating to the company’s stock. The stock has a consensus rating of “Hold” and a consensus price target of $15.00.

Momenta Pharmaceuticals Profile

Momenta Pharmaceuticals, Inc is a biotechnology company. The Company is focused on developing generic versions of drugs, biosimilars and therapeutics for oncology and autoimmune disease. The Company has developed generic version of LOVENOX (enoxaparin sodium injection) and COPAXONE (glatiramer acetate injection).

Institutional Ownership by Quarter for Momenta Pharmaceuticals (NASDAQ:MNTA)

Receive News & Stock Ratings for Momenta Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Momenta Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.